Jinyuan Lu

Jinyuan Lu

Auto-generated profile, based on publicly available information

Jinyuan Lu

School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2024 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
STSaisai Tian
Saisai Tian
XLXuyang Liao
Xuyang Liao
WCWen Cao
Wen Cao
XWXinyi Wu
Xinyi Wu
ZCZexi Chen
Zexi Chen
WZWei-Dong Zhang
Wei-Dong Zhang
Pharmacotranscriptomic profiles, which capture drug-induced changes in gene expression, offer vast potential for computational drug discovery and are widely used in modern medicine. However, current computational approaches neglected the associations within gene‒gene functional networks and unrevealed the systematic relationship between drug efficacy and the reversal effect. Here, we developed a new genome-scale functional module (GSFM) transformation framework to quantitatively evaluate drug efficacy for in silico drug discovery. GSFM employs four biologically interpretable quantifiers: GSFM_Up, GSFM_Down, GSFM_ssGSEA, and GSFM_TF to comprehensively evaluate the multi-dimension activities of each functional module (FM) at gene-level, pathway-level, and transcriptional regulatory network-level. Through a data transformation strategy, GSFM effectively converts noisy and potentially unreliable gene expression data into a more dependable FM active matrix, significantly outperforming other methods in terms of both robustness and accuracy. Besides, we found a positive correlation between RSGSFM and drug efficacy, suggesting that RSGSFM could serve as representative measure of drug efficacy. Furthermore, we identified WYE-354, perhexiline, and NTNCB as candidate therapeutic agents for the treatment of breast-invasive carcinoma, lung adenocarcinoma, and castration-resistant prostate cancer, respectively. The results from in vitro and in vivo experiments have validated that all identified compounds exhibit potent anti-tumor effects, providing proof-of-concept for our computational approach.

6 February 2026 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
STSaisai Tian
Saisai Tian
YLYixue Liang
Yixue Liang
JZJinbo Zhang
Jinbo Zhang
WLWeishan Liang
Weishan Liang
JLJinyuan Lu
Jinyuan Lu
WZWei-Dong Zhang
Wei-Dong Zhang
Gene essentiality (synonymous with dependency) mapping reveals therapeutic vulnerabilities for intractable oncogenes, yet integrated platforms bridging CRISPR functional genomics with drug discovery remain limited. To address this gap, we developed GEMap, A Gene Essentiality-Guided Platform for Drug Discovery, by combining genome-wide CRISPR-Cas9 essentiality profiles (1912 screens across 1135 cancer cell lines) with multi-omics annotations, drug profiles and drug targets information (20,000+ compounds). GEMap can be used to (1) explore multimodal gene data (Dependency/Expression/CNV/Mutation) across cell lines and tissues; (2) prioritize context-specific therapeutic targets by quantifying differential genetic dependencies in molecularly stratified cancers, such as KRAS mutant-cancers; and (3) discover tailored treatments and drug candidates targeting particular gene using large-scale drug perturbation data and drug physical targets. To the best of our knowledge, GEMap represents the first platform bridging CRISPR-derived genetic dependencies with pharmacological responses and biological networks and establishes an open-access paradigm for accelerating precision oncology against undruggable targets. GEMap is available at https://web.biotcm.net/GEMap/.

26 March 2021 in American Behavioral Scientist
Verified
Journal Article
Open access
PDF file
XYXuewen Yan
Xuewen Yan
TQTianyao Qu
Tianyao Qu
NSNathan Sperber
Nathan Sperber
JLJinyuan Lu
Jinyuan Lu
MFMengzhen Fan
Mengzhen Fan
BCBenjamin Cornwell
Benjamin Cornwell
Expanding on recent research on the transmission of COVID-19 via social networks, this article argues that exposure to familial and other close contacts who already have the disease may increase the severity of one’s subsequent illness. We hypothesize that having family members or close contacts who were diagnosed with COVID-19 before one’s own diagnosis exacerbates illness severity due to several potential mechanisms including changes in available social support access, increased stress and strain, and increased viral load due to the nature of one’s exposure to the novel coronavirus. We analyze administrative data of all 417 patients who were diagnosed with COVID-19 in the Chinese city of Shenzhen between January 8 and February 25, 2020. Our analyses show that, when patients had family members or close ties diagnosed with COVID-19, they experienced more severe illness. We also find that patients with infected family members or close contacts did not have significantly extended total illness duration, due to their reduced time to diagnosis. The implications of both findings are discussed.

31 March 2026 in Chinese Herbal Medicines
Verified
Journal Article
Open access
JLJinyuan Lu
Jinyuan Lu
WLWeishan Liang
Weishan Liang
YLYixue Liang
Yixue Liang
JRJiajia Ren
Jiajia Ren
CGChengyang Guo
Chengyang Guo
STSaisai Tian
Saisai Tian

27 July 2026 in Engineering
Verified
Journal Article
Open access
STSaisai Tian
Saisai Tian
JLJinyuan Lu
Jinyuan Lu
CGChengyang Guo
Chengyang Guo
WGWenjing Gu
Wenjing Gu
PHPengli Huang
Pengli Huang
WZWeidong Zhang
Weidong Zhang

18 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
BZBingmiao Zhuang
Bingmiao Zhuang
WGWenjing Gu
Wenjing Gu
ALAnrong Liu
Anrong Liu
JCJing Chen
Jing Chen
JGJingshan Gao
Jingshan Gao
STSaisai Tian
Saisai Tian
Immune checkpoint inhibitors (ICIs) have substantially improved clinical outcomes across multiple cancer types, yet durable clinical benefit remains limited to a subset of patients. Robust biomarkers that are both predictive and biologically interpretable are still lacking. Here, we present a network-based interpretable machine learning framework for immunotherapy response prediction using pathway-level features derived from the human protein–protein interaction (PPI) network. Starting from established immunotherapy targets, we applied random walk with restart to prioritize target-associated genes, extracted core network modules, and quantified their topological proximity to KEGG pathways to define biologically informed pathway features. These features were then incorporated into machine learning models and evaluated across 11 immunotherapy cohorts, comprising 1,237 patients across multiple cancer types and treatment settings. The resulting pathway-based models showed stable predictive performance in both within-cohort and cross-cohort analyses and were generally superior or comparable to conventional gene-based and immune-feature-based approaches. Beyond prediction, the framework also captured immune-related biological characteristics. In TCGA-SKCM, pathway activity was positively associated with CD8+ T-cell infiltration and negatively associated with M2 macrophage abundance. In the IMvigor210 cohort, PD-L1-related pathway features further distinguished distinct tumor immune phenotypes. Together, our findings provide an interpretable computational framework that links network organization, pathway activity, and immunotherapy response, and provides a biologically grounded strategy for response prediction and immune-state characterization.